DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Tandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...

(Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Studies show the potential for Dexcom CGM to support therapy de-escalation and optimise diabetes management in Type 2 diabetes. 5,6,8 EDINBURGH, Scotland, September 04, 2024--(BUSINESS WIRE ...

The Dexcom G7 CGM System is designed to be user-friendly ... expected to reach $35.8 billion by 2028 at a growth rate of 13.6%. The market is being driven by escalating diabetes care solutions ...

Stock analysis is all about predictions – but as wits from Mark Twain to Yogi Berra have reminded us, predictions are hard, ...

Studies show the potential for Dexcom CGM to support therapy de-escalation and optimise diabetes management in Type 2 diabetes. 5,6,8 EDINBURGH, Scotland, September 04, 2024--(BUSINESS WIRE)--DexCom, ...

The Dexcom G7 CGM System is designed to be user-friendly ... be $18.9 billion in 2023 and is expected to reach $35.8 billion by 2028 at a growth rate of 13.6%. The market is being driven by escalating ...